Cardiac Manifestation in a Child With Atypical Hemolytic Uremic Syndrome

Abstract

Get full access to this article

View all access options for this article.

References

Daraz

Abdelghffar

OH.

Lidocaine infusion: an antiarrhythmic with neurologic toxicities. Cureus. 2022;14(3):e23310.

Noris

Remuzzi

Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2014;10(3):174-180.

Marzuillo

Benettoni

Germani

Ferrara

D’Agata

Barbi

Acquired long QT syndrome: a focus for the general pediatrician. Pediatr Emerg Care. 2014;30:257-261.

Drew

Ackerman

Funk

, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047-1060.

Prakash

Gupta

Kumar

Rawat

UB.

Recurrent ventricular tachycardia complicating atypical haemolytic-uraemic syndrome. Nephrol Dial Transplant. 1998;13(9):2419-2420.

Ridolfi

Hutchins

Bell

WR.

The heart and cardiac conduction system in thrombotic thrombocytopenic purpura: a clinicopathologic study of 17 autopsied patients. Ann Intern Med. 1979;91(3):357-363.

Nester

Barbour

de Cordoba

, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31-42.

Yang

Song

, et al. The role of the complement factor B‒arginase‒polyamine molecular axis in uremia-induced cardiac remodeling in mice. Eur J Immunol. 2020;50(2):220-233.

Chun

Haddadin

Liu

, et al. Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury. PLoS ONE. 2017;12(6):e0179450.